Article Details

Regeneron's bispecific lymphoma antibody odronextamab wins FDA priority review

Retrieved on: 2023-09-30 00:33:25

Tags for this article:

Click the tags to see associated articles and topics

Regeneron's bispecific lymphoma antibody odronextamab wins FDA priority review. View article details on hiswai:

Excerpt

GlobalData is the parent company of Pharmaceutical Technology. ... We may store and access personal data such as cookies, device identifiers or other ...

Article found on: www.pharmaceutical-technology.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up